Literature DB >> 4598296

A hyperglycemic peptide from pituitary growth hormone: preparation with pepsin and assay in ob-ob mice.

A J Lostroh, M E Krahl.   

Abstract

A fragment that induces glucose intolerance in hereditarily obese mice has been prepared from pituitary growth hormone(sheep and human) by controlled digestion with pepsin in 0.05 M sodium acetate buffer, pH 3.7. The digest was purified by column chromatography on Bio-Gel P-6, followed by chromatography on Bio-Rex 70 and Bio-Gel P-2; in each successive step peptide was quantitated with the fluorescamine procedure. The fragment from sheep growth hormone has these characteristics: (1) It induces glucose intolerance in fasted ob/ob female mice when injected subcutaneously in a divided dose 15 min before, and concurrently with, glucose. (2) It is a basie peptide, as judged from its elution behavior on Bio-Rex 70, H(+) form. (3) It does not crossreact with antiserum to human growth hormone in radioimmunoassay. Further purification and initial sequence determinations have been undertaken.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4598296      PMCID: PMC388201          DOI: 10.1073/pnas.71.4.1244

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

1.  The effect of insulin and pituitary hormones on glucose uptake in muscle.

Authors:  M E KRAHL
Journal:  Ann N Y Acad Sci       Date:  1951-12       Impact factor: 5.691

2.  Some effects of purified pituitary growth hormone on carbohydrate metabolism in the rat.

Authors:  A E MILMAN; J A RUSSELL
Journal:  Endocrinology       Date:  1950-08       Impact factor: 4.736

3.  Limited pepsin digestion of bovine plasma albumin.

Authors:  T P King
Journal:  Arch Biochem Biophys       Date:  1973-06       Impact factor: 4.013

Review 4.  The physiology of growth hormone regulation: pre- and postimmunoassay eras.

Authors:  S Reichlin
Journal:  Metabolism       Date:  1973-08       Impact factor: 8.694

5.  Quantitative study of the diabetogenic action of ACTH and growth hormone in partially pancreatectomized rats.

Authors:  R W Bates; M M Garrison
Journal:  Endocrinology       Date:  1967-09       Impact factor: 4.736

6.  The lipid-mobilizing effect of some pituitary gland preparations. IV. Subdivision of a human growth hormone preparation into a somatotrophic and an adipokinetic-hyperglycaemic agent.

Authors:  O Trygstad; I Foss
Journal:  Acta Endocrinol (Copenh)       Date:  1968-06

7.  A proposed mechanism of the diabetogenic action of growth hormone and its relation to the action of insulin.

Authors:  J Bornstein
Journal:  Isr J Med Sci       Date:  1972-03

8.  Amino acid sequence of a biologically active fragment of bovine growth hormone.

Authors:  N Yamasaki; K Kangawa; S Kobayashi; M Kikutani; M Sonenberg
Journal:  J Biol Chem       Date:  1972-06-25       Impact factor: 5.157

9.  Studies on the cross-reaction between human growth hormone and human chorionic somatomammotropin in radioimmunoassay systems.

Authors:  D B Grant; S L Kaplan; M M Grumbach
Journal:  J Clin Endocrinol Metab       Date:  1971-01       Impact factor: 5.958

10.  Growth hormone covalently bound to Sepharose. II. Study of the biological activity of a growth hormone-Sepharose complex in adipose tissue and diaphragm muscle.

Authors:  J Schwartz; D F Nutting; H M Goodman; J L Kostyo; R E Fellows
Journal:  Endocrinology       Date:  1973-02       Impact factor: 4.736

View more
  3 in total

Review 1.  Diabetogenic activity of the anterior pituitary (a progress report).

Authors:  G F Tutwiler
Journal:  Acta Diabetol Lat       Date:  1976 Sep-Dec

2.  Diabetogenic peptide from human growth hormone: partial purification from peptic digest and long-term action in ob/ob mice.

Authors:  A J Lostroh; M E Krahl
Journal:  Proc Natl Acad Sci U S A       Date:  1976-12       Impact factor: 11.205

Review 3.  Human Growth and Growth Hormone: From Antiquity to the Recominant Age to the Future.

Authors:  Evan Graber; Edward O Reiter; Alan D Rogol
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.